Articles & Video
Report: Oligonucleotide, Peptide, mRNA and Genome Edited Therapeutics State of the Industry 2021
How has the oligonucleotide, peptide, mRNA and genome editing sector transformed over the last year? This industry report provides insight.
eBook: Personalized Peptide Vaccines & Therapies
This ebook focuses on the latest challenges and approaches in producing personalized therapies and vaccines to fight cancer and rare diseases.
45% of companies in oligonucleotide, peptide and mRNA therapeutics increased collaboration during the pandemic
We examine the effects on collaboration in the peptide, oligonucleotide and mRNA therapeutics industry as a result of the COVID-19 pandemic.
Keep up to date with content on Peptide & Oligonucleotide Therapeutics
Keep up to speed every month with top content on peptide, oligonucleotide and mRNA therapeutics.
Personalized Medicine: Neoantigen Cancer Vaccines and T Cell Therapy
We look at precision antigen selection carried out with a personalized immune response profiling platform, demonstrated at TIDES: Oligonucleotide and Peptide Therapeutics.
Delivery is still biggest area of need in peptide, oligonucleotide and mRNA therapeutics
We examine recent trends in technology needs and macromolecular delivery for oligonucleotide, peptide, mRNA and genome edited therapeutics.
A look back at TIDES Asia Virtual Scientific Forum 2021
We explore the best of on-demand webinars from this year's TIDES Asia Virtual Scientific Forum.
Scaling up manufacturing when it’s needed most
Learn how Thermo Fisher Scientific scaled up raw material manufacturing for mRNA production, leaning on decades of experience.
Analytical and regulatory CMC strategies for oligonucleotide therapeutics
We explore the latest analytical and regulatory insights into the CMC of oligonucleotide therapies.
SURVEY: Diversity, Equity and Inclusion in the Life Sciences 2021
Complete our survey on Diversity, Equity and Inclusion in the Life Sciences 2021 to get exclusive early access to the final report.
TIDES Europe Virtual 2020: Post-event Report
This report looks back at the top sessions and features of this year's TIDES Europe Virtual.
Post-event Report - TIDES: Oligonucleotide and Peptide Therapeutics
September 2020 saw the first TIDES event made virtual. This report provides a summary of the key topics, highlights and sessions of the week.
Report: Partnering And Deal-Making in Pharma through the Pandemic
This Informa report explores how partnering and deal-making in the pharma industry has been impacted by COVID-19.
REPORT: The Future of Healthcare Post COVID-19
In our latest report learn how healthcare organizations are adapting to succeed post COVID-19, from innovation to product development.
Diversity and Inclusion in Biotech
The life science industry has a challenge to become more equal, diverse and inclusive. Join us at Diversity and Inclusion in Biotech, September 22nd and find out how TOGETHER we can make a difference.
SURVEY: Partnering and Deal-Making in Biopharma through the Pandemic
We are conducting a huge study to gauge perspectives around biopharma deal-making during COVID-19 and the commercial ramifications of the pandemic. Take part here.
The Future of the Oligonucleotide and Peptide Therapeutics Industry
What changes could happen in the oligonucleotide and peptide therapeutics industry over the next decade? This interactive ebook gathers predictions from industry professionals all over the globe.
42% of pharma industry believe cell and gene therapies to be most promising therapeutics
According to a recent study, 42% of pharma industry professionals predict cell and gene therapies are the therapeutic area that will see the fastest growth in the next 10 years.
Peptide Therapies — Small Biomolecules Address Big Health Problems
This BioProcess International ebook looks at product research, manufacturing and regulatory concerns within the promising world of peptide therapies.
Oligonucleotides and peptides: the regulatory challenges
We investigate where current regulatory obstacles lie surrounding peptide and oligonucleotide therapeutics.
80% of life sciences professionals predict a COVID-19 vaccine will be approved within 18 months
How quickly to life sciences professionals predict a COVID-19 vaccine will be approved and what are the main obstacles? We explore.